Journal Articles Conference Presentations Book Chapters Public Presentations

A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

Alton EW, Boyd AC, Porteous DJ, Davies G, Davies JC, Griesenbach U, Higgins TE, Gill DR, Hyde SC, Innes JA

American Journal of Respiratory and Critical Care Medicine

AJRCCM, Volume 192, Pages 1389-1392

 Download the Manuscript

Print this page

Go Back to Publications     View on Pubmed (26623687)    View on Google Scholar


 

Other Publications by these authors
Lung clearance index in primary ciliary dyskinesia and bronchiectasis.
Irving SJ et al. American Journal Of Respiratory And Critical Care Medicine (2014) Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Alton EW et al. Gene Therapy (2013) The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
Alton EW et al. Biomaterials (2013) A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Alton EW et al. Thorax (2013) Expert opinion in biological therapy: update on developments in lung gene transfer.
Griesenbach U et al. Expert Opinion On Biological Therapy (2013) Oral contraceptives do not appear to affect cystic fibrosis disease severity.
Kernan NG et al. The European Respiratory Journal (2012)